Estimation of background incidence rates of guillain-barré syndrome in Germany-A retrospective cohort study with electronic healthcare data

Neuroepidemiology

Volumn 43, Issue 3-4, 2014, Pages 244-252

  Hense, Sabrina ^a   Schink, Tania ^a   Kreisel, Stefan H ^b   Marcelon, Lydie ^c   Simondon, François ^c   Tahden, Maike ^a   Garbe, Edeltraut ^a,d  

^a LEIBNIZ INSTITUTE FOR PREVENTION RESEARCH AND EPIDEMIOLOGY BIPS   (Germany)

^b EVANGELISCHES KRANKENHAUS   (Germany)

^c SANOFI PASTEUR   (France)

^d UNIVERSITY OF BREMEN   (Germany)

Author keywords

Administrative data; Guillain Barr Syndrome; Polyneuropathy; Vaccine safety

Indexed keywords

VACCINE;

ADULT; ARTICLE; COHORT ANALYSIS; DIAGNOSTIC PROCEDURE; ELECTRONIC MEDICAL RECORD; FEMALE; GEOGRAPHY; GERMANY; GROUPS BY AGE AND SEX; GUILLAIN BARRE SYNDROME; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; RISK ASSESSMENT; SEASON; ADOLESCENT; AGE; AGE DISTRIBUTION; AGED; CHILD; GUILLAIN-BARRE SYNDROME; INFANT; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SEX DIFFERENCE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGE FACTORS; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; ELECTRONIC HEALTH RECORDS; FEMALE; GERMANY; GUILLAIN-BARRE SYNDROME; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEASONS; SEX FACTORS; YOUNG ADULT;

EID: 84920003386     PISSN: 02515350     EISSN: 14230208     Source Type: Journal    
DOI: 10.1159/000369344     Document Type: Article

References (44)

1. Yuki N, Hartung HP: Guillain-Barre syndrome. N Engl J Med 2012; 366: 2294-2304.
2. Hughes RA, Cornblath DR: Guillain-Barre syndrome. Lancet 2005; 366: 1653-1666.
3. Hadden RD, Karch H, Hartung HP, Zielasek J, Weissbrich B, Schubert J, et al: Preceding infections, immune factors, and outcome in Guillain-Barre syndrome. Neurology 2001; 56: 758-765.
4. Hartung HP, Keller-Stanislawski B, Hughes RA, Lehmann HC: [Guillain-Barre syndrome after exposure to influenza]. Nervenarzt 2012; 83: 714-730.
5. Jacobs BC, Rothbarth PH, van der Meche FG, Herbrink P, Schmitz PI, de Klerk MA, et al: The spectrum of antecedent infections in Guillain-Barre syndrome: a case-control study. Neurology 1998; 51: 1110-1115.
6. Kang JH, Sheu JJ, Lin HC: Increased risk of Guillain-Barre Syndrome following recent herpes zoster: a population-based study across Taiwan. Clin Infect Dis 2010; 51: 525-530.
7. Poropatich KO, Walker CL, Black RE: Quantifying the association between Campylobacter infection and Guillain-Barre syndrome: a systematic review. J Health Popul Nutr 2010; 28: 545-552.
8. Sivadon-Tardy V, Orlikowski D, Porcher R, Sharshar T, Durand MC, Enouf V, et al: Guillain-Barre syndrome and influenza virus infection. Clin Infect Dis 2009; 48: 48-56.
9. Winner SJ, Evans JG: Age-specific incidence of Guillain-Barre syndrome in Oxfordshire. Q J Med 1990; 77: 1297-1304.
10. Bardage C, Persson I, Ortqvist A, Bergman U, Ludvigsson JF, Granath F: Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden. BMJ 2011; 343:d5956.
11. De Wals P, Deceuninck G, Toth E, Boulianne N, Brunet D, Boucher RM, et al: Risk of Guillain-Barre syndrome following H1N1 influenza vaccination in Quebec. JAMA 2012; 308: 175-181.
12. Dieleman J, Romio S, Johansen K, Weibel D, Bonhoeffer J, Sturkenboom M: Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe. BMJ 2011; 343:d3908.
13. Gee J, Naleway A, Shui I, Baggs J, Yin R, Li R, et al: Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine 2011; 29: 8279-8284.
14. Nelson KE: Invited commentary: influenza vaccine and Guillain-Barre syndrome-is there a risk Am J Epidemiol 2012; 175: 1129-1132.
15. Paul Ehrlich Institut: Zusammenhang zwischen pandemischer Influenza A/H1N1v-Impfung und Guillain-Barré-Syndrom/Miller-Fisher-Syndrom in Deutschland. http://www. pei.de/cln-101/nn-2248804/DE/arzneimittel sicherheit-vigilanz/pharmakovigilanz/for schung/gbs-studie/gbs-guillan-barre-syn drom-studie-node.html-nnn=true# doc 2338784bodyText3 (accessed June 26, 2014).
16. Souayah N, Nasar A, Suri MF, Qureshi AI: Guillain-Barre syndrome after vaccination in United States a report from the CDC/FDA Vaccine Adverse Event Reporting System. Vaccine 2007; 25: 5253-5255.
17. Souayah N, Nasar A, Suri MF, Qureshi AI: Guillain-Barre syndrome after vaccination in United States: data from the Centers for Disease Control and Prevention/Food and Drug Administration Vaccine Adverse Event Reporting System (1990-2005). J Clin Neuromuscul Dis 2009; 11: 1-6.
18. Souayah N, Michas-Martin PA, Nasar A, Krivitskaya N, Yacoub HA, Khan H, et al: Guillain-Barre syndrome after Gardasil vaccination: data from Vaccine Adverse Event Reporting System 2006-2009. Vaccine 2011; 29: 886-889.
19. Tokars JI, Lewis P, Destefano F, Wise M, Viray M, Morgan O, et al: The risk of Guillain-Barre syndrome associated with influenza A (H1N1) 2009 monovalent vaccine and 2009-2010 seasonal influenza vaccines: results from self-controlled analyses. Pharmacoepidemiol Drug Saf 2012; 21: 546-552.
20. Velentgas P, Amato AA, Bohn RL, Chan KA, Cochrane T, Funch DP, et al: Risk of Guillain-Barre syndrome after meningococcal conjugate vaccination. Pharmacoepidemiol Drug Saf 2012; 21: 1350-1358.
21. Wise ME, Viray M, Sejvar JJ, Lewis P, Baughman AL, Connor W, et al: Guillain-Barre syndrome during the 2009-2010 H1N1 influenza vaccination campaign: population-based surveillance among 45 million Americans. Am J Epidemiol 2012; 175: 1110-1119.
22. Sejvar JJ, Baughman AL, Wise M, Morgan OW: Population incidence of Guillain-Barre syndrome: a systematic review and metaanalysis. Neuroepidemiology 2011; 36: 123-133.
23. Lehmann HC, Kohne A, Meyer zu Horste G, Kieseier BC: Incidence of Guillain-Barre syndrome in Germany. J Peripher Nerv Syst 2007; 12: 285.
24. Black S, Eskola J, Siegrist CA, Halsey N, Macdonald N, Law B, et al: Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet 2009; 374: 2115-2122.
25. Garbe E, Suling M, Kloss S, Lindemann C, Schmid U: Linkage of mother-baby pairs in the German Pharmacoepidemiological Research Database. Pharmacoepidemiol Drug Saf 2011; 20: 258-264.
26. Kraut AA, Schink T, Schulze-Rath R, Mikolajczyk RT, Garbe E: Incidence of anogenital warts in Germany: a population-based cohort study. BMC Infect Dis 2010; 10: 360.
27. Lindemann C, Langner I, Kraut AA, Banaschewski T, Schad-Hansjosten T, Petermann U, et al: Age-specific prevalence, incidence of new diagnoses, and drug treatment of attention-deficit/hyperactivity disorder in Germany. J Child Adolesc Psychopharmacol 2012; 22: 307-314.
28. Pigeot I, Ahrens W: Establishment of a pharmacoepidemiological database in Germany: methodological potential, scientific value and practical limitations. Pharmacoepidemiol Drug Saf 2008; 17: 215-223.
29. Daly LE: Confidence limits made easy: interval estimation using a substitution method. Am J Epidemiol 1998; 147: 783-790.
30. Gesundheitsberichterstattung des Bundes. Standardbevölkerung. http://www.gbe-bund. de (accessed June 26, 2014).
31. Rasmussen TA, Jorgensen MR, Bjerrum S, Jensen-Fangel S, Stovring H, Ostergaard L, et al: Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study. BMJ 2012; 345:e5823.
32. McLean M, Duclos P, Jacob P, Humphreys P: Incidence of Guillain-Barre syndrome in Ontario and Quebec, 1983-1989, using hospital service databases. Epidemiology 1994; 5: 443-448.
33. Criteria for diagnosis of Guillain-Barre syndrome. Ann Neurol 1978; 3: 565-566.
34. Asbury AK, Cornblath DR: Assessment of current diagnostic criteria for Guillain-Barre syndrome. Ann Neurol 1990; 27(suppl):S21-S24.
35. Sejvar JJ, Kohl KS, Gidudu J, Amato A, Bakshi N, Baxter R, et al: Guillain-Barre syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2011; 29: 599-612.
36. Funch D, Holick C, Velentgas P, Clifford R, Wahl PM, McMahill-Walraven C, et al: Algorithms for identification of Guillain-Barre Syndrome among adolescents in claims databases. Vaccine 2013; 31: 2075-2079.
37. van der Maas NA, Kramer MA, Jacobs BC, van Soest EM, Dieleman JP, Kemmeren JM, et al: Guillain-Barre syndrome: background incidence rates in The Netherlands. J Peripher Nerv Syst 2011; 16: 243-249.
38. Arbeitsgemeinschaft Influenza: Abschlussbericht der Influenzasaison 2006/2007. Robert Koch Institut, 2007.
39. Arbeitsgemeinschaft Influenza: Abschlussbericht der Influenzasaison 2007/2008. Robert Koch Institut, 2008.
40. Arbeitsgemeinschaft Influenza: Abschlussbericht der Influenzasaison 2008/2009. Robert Koch Institut, 2009.
41. Epidemiologisches Bulletin 21/2010: Rückblick: Epidemiologie und Infektionsschutz im zeitlichen Verlauf der Influenzapandemie (H1N1) 2009 Robert Koch Institut. http://www.rki.de/DE/Content/InfAZ/I/Influenza/Pandemie/Pandemie-Node.html (accessed June 26, 2014).
42. Frenzen PD: Economic cost of Guillain-Barre syndrome in the United States. Neurology 2008; 71: 21-27.
43. Korinthenberg R, Gold R, Felderhoff-Müser U: Leitlinie der Gesellschaft für Neuropädiatrie: Guillain-Barré Syndrom im Kindes-und Jugendalter. http://www.awmf.org/leitlinien/detail/ll/022-008.html (accessed June 26, 2014).
44. Rees JH, Hughes RA: Campylobacter jejuni infection and childhood Guillain-Barre syndrome. Ann Neurol 1994; 35: 248-249.